| NCT06878560 | Study to Evaluate the Safety and Efficacy of the 10 GE Xenokidney in Patients With ESRD | RECRUITING | PHASE1, PHASE2 | 2025-08 | 2075-08 | 2075-08 |
| NCT03149211 | To Investigate the Efficacy and Safety of UB-421 Monotherapy in HIV-1 Infected Adults | WITHDRAWN | PHASE3 | 2025-04-01 | 2025-12-31 | 2025-12-31 |
| NCT06488274 | Evolution of Functional Gastrointestinal Disorders in Infants Fed With a New Infant Formula | RECRUITING | NA | 2024-10-21 | 2026-04 | 2025-12 |
| NCT06481280 | Evaluation of Tolerance, Efficacy and Safety of an Hydrolyzed Formula in Infants With IgE/Non-IgE Mediated CMA. | ACTIVE_NOT_RECRUITING | NA | 2024-08-14 | 2026-06 | 2026-01 |
| NCT04620291 | Study for Evaluation of the Safety, Pharmacokinetics, and Antiviral Activity of UB-421 Subcutaneous Formulation in HIV Infected Adults | NOT_YET_RECRUITING | PHASE1 | 2023-12-31 | 2025-12-31 | 2025-12-31 |
| NCT04175704 | Evaluating the Safety and Tolerability and Determining the PK and PD of Single Dose UB-221 in Chronic Spontaneous Urticaria | NOT_YET_RECRUITING | PHASE1 | 2023-12-30 | 2026-01-30 | 2024-11-30 |
| NCT04406727 | UB-421 in Combination With Optimized Background Regimen in Patients With Multi-drug Resistant HIV-1 Infection | NOT_YET_RECRUITING | PHASE3 | 2023-12-01 | 2026-06-30 | 2026-06-30 |
| NCT03164447 | UB-421 Combine With Optimized Background Therapy Regimen in Multi-Drug Resistant HIV-1 Infection Patients | UNKNOWN | PHASE2 | 2023-12 | 2024-05 | 2024-03 |
| NCT05943535 | Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) | RECRUITING | PHASE3 | 2023-10-30 | 2027-11 | 2027-11 |
| NCT03595995 | A Phase 2 Trial to Evaluate the Safety and Efficacy of UB-621 | UNKNOWN | PHASE2 | 2023-06-01 | 2024-06-30 | 2024-06-30 |
| NCT05203510 | A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension | ACTIVE_NOT_RECRUITING | PHASE4 | 2022-10-20 | 2028-04-30 | 2026-04-30 |
| NCT05298215 | A Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Efficacy of UB-221 IV Infusion as an add-on Therapy in Patients With Chronic Spontaneous Urticaria | UNKNOWN | PHASE2 | 2022-10-05 | 2023-12-31 | 2023-12-31 |
| NCT05255991 | Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | COMPLETED | PHASE3 | 2022-10-04 | 2025-06-30 | 2025-06-30 |
| NCT04905693 | Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease | ENROLLING_BY_INVITATION | PHASE3 | 2022-09-06 | 2026-06 | 2026-06 |
| NCT05340712 | Evaluation of the Efficacy of a New Specific Infant Formula in Case of Functional Constipation | UNKNOWN | NA | 2022-07-20 | 2024-09 | 2023-12 |
| NCT05318300 | Evaluation of an Adapted Formula on Atopic Dermatitis. | ACTIVE_NOT_RECRUITING | NA | 2022-05-24 | 2024-04 | 2024-04 |
| NCT05056974 | A Proof-of-concept Trial to Evaluate the Safety and Efficacy of UB-421 Plus Chidamide in Changing HIV Reservoirs | COMPLETED | PHASE2 | 2021-12-02 | 2023-02-01 | 2023-02-01 |
| NCT04708782 | Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | ACTIVE_NOT_RECRUITING | PHASE3 | 2021-06-01 | 2026-01 | 2026-01 |
| NCT04810026 | Transform Type 2: Examining Meal-Delivery and Education for Diabetes Self-Care | COMPLETED | NA | 2021-05-03 | 2021-10-26 | 2021-10-26 |
| NCT04084678 | A Study of Ralinepag to Evaluate Effects on Exercise Capacity by CPET in Subjects With WHO Group 1 PH | TERMINATED | PHASE3 | 2021-01-20 | 2023-04-12 | 2023-04-12 |
| NCT04656691 | At-Home Infusion Using Bamlanivimab in Participants With Mild to Moderate COVID-19 | TERMINATED | PHASE4 | 2021-01-04 | 2021-04-18 | 2021-04-18 |
| NCT04620304 | Study for Evaluation of the Safety, Pharmacokinetics, and Antiviral Activity of UB-421 Subcutaneous Formulation Administered in HIV-1 Infected Treatment Naive Patients | COMPLETED | PHASE1 | 2021-01-01 | 2022-05-25 | 2022-05-25 |
| NCT04358146 | Study on the Efficacy and Tolerance of a New Anti-regurgitation Infant Formula (STELLAR) | UNKNOWN | NA | 2020-07-01 | 2022-03-01 | 2022-01-01 |
| NCT04353037 | PATCH 2&3:Prevention & Treatment of COVID-19 (Severe Acute Respiratory Syndrome Coronavirus 2) With Hydroxychloroquine | TERMINATED | PHASE2 | 2020-04-07 | 2020-07-11 | 2020-07-11 |
| NCT04041362 | the Study to Evaluate the Safety of UB-421 in Combination With Antiretroviral Therapy (ART) and the Efficacy in Reduction of HIV Viral Load and Proviral DNA as Compared to ART Alone in ART-experienced Viremic HIV-1 Patients | WITHDRAWN | PHASE2 | 2020-04 | 2021-03 | 2020-12 |
| NCT05151055 | Lactoferrin + Vitamin E + Zinc for Hormonal Acne | UNKNOWN | PHASE2 | 2020-03-02 | 2022-09 | 2022-06 |
| NCT03857841 | A Safety Study of IV Stem Cell-derived Extracellular Vesicles (UNEX-42) in Preterm Neonates at High Risk for BPD | TERMINATED | PHASE1 | 2019-10-09 | 2021-05-20 | 2021-05-20 |
| NCT03683186 | A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | ENROLLING_BY_INVITATION | PHASE3 | 2019-09-23 | 2026-12 | 2026-12 |
| NCT03950739 | Open-label, Clinical Study to Evaluate the Safety and Tolerability of TreT in Subjects With PAH Currently Using Tyvaso | COMPLETED | PHASE1 | 2019-09-17 | 2023-08-22 | 2023-08-22 |
| NCT03632291 | Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UB-221 as an Add-on Therapy in CSU Patients | COMPLETED | PHASE1 | 2019-04-09 | 2021-01-19 | 2021-01-19 |
| NCT03497689 | EXPEDITE: A Study of Remodulin Induction Followed by Orenitram Optimization to Treat Pulmonary Arterial Hypertension | COMPLETED | PHASE4 | 2019-01-31 | 2022-05-11 | 2022-05-11 |
| NCT03999437 | SINGLE-APPLICATION TERBINAFINE HYDROCHLORIDE (1%) TOPICAL LIQUID SOLUTION VERSUS A SINGLE-APPLICATION BUTENAFINE HYDROCHLORIDE (1%) TOPICAL LIQUID SOLUTION FOR THE TREATMENT OF TINEA PEDIS | UNKNOWN | PHASE2 | 2019-01-02 | 2020-01-03 | 2019-12-13 |
| NCT03794583 | Inhaled Treprostinil in Participants With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD) | TERMINATED | PHASE3 | 2018-12-21 | 2022-11-29 | 2022-11-29 |
| NCT03743376 | The HIV Functional Cure Potential of UB-421 in ART Stabilized HIV-1 Patients | COMPLETED | PHASE2 | 2018-12-12 | 2021-12-31 | 2020-10-15 |
| NCT03626688 | A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients | ACTIVE_NOT_RECRUITING | PHASE3 | 2018-08-30 | 2025-12 | 2025-12 |
| NCT03557671 | Evaluation of the Hypoallergenicity of a New Formula Based on Hydrolyzed Rice Proteins | COMPLETED | NA | 2018-08-23 | 2020-09-21 | 2020-09-21 |
| NCT03496623 | A Phase 3 Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Participants With Pulmonary Hypertension (PH) Due to Chronic Obstructive Pulmonary Disease (COPD) | TERMINATED | PHASE3 | 2018-05-08 | 2022-10-13 | 2022-10-13 |
| NCT03460860 | Astaxanthin (2 mg) + Lycopene (1.8 mg) + D-Alpha-Tocopherol (10 IU) For The Treatment Of Skin Aging | COMPLETED | NA | 2018-03-05 | 2019-02-07 | 2018-10-10 |
| NCT03013881 | A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of UB-921 in Healthy Volunteers | COMPLETED | PHASE1 | 2018-03-05 | 2019-04-02 | 2018-10-08 |
| NCT03043651 | Open-label Extension of Oral Treprostinil in Subjects With PH Associated With HFpEF | TERMINATED | PHASE3 | 2018-01-30 | 2020-03-02 | 2020-03-02 |
| NCT02999906 | Study to Compare Triple Therapy (Oral Treprostinil, Ambrisentan, and Tadalafil) With Dual Therapy (Ambrisentan, Tadalafil, and Placebo) in Subjects With Pulmonary Arterial Hypertension | WITHDRAWN | PHASE3 | 2017-10 | 2022-06 | 2021-12 |
| NCT03286101 | Efficacy and Safety of Topical 0.5% Ivermectin Lotion for the Treatment of Head Lice Infestation in Filipinos | COMPLETED | PHASE2 | 2017-09-14 | 2017-11-09 | 2017-10-12 |
| NCT03037580 | Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction | TERMINATED | PHASE3 | 2017-08-15 | 2019-12-03 | 2019-12-03 |
| NCT03098030 | Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Cancer | COMPLETED | PHASE2, PHASE3 | 2017-06-01 | 2020-03-26 | 2020-01-27 |
| NCT02882126 | An Open Label Extension Study to Evaluate the Safety of Continued Therapy of Subcutanous Remodulin® in Pulmonary Arterial Hypertension | WITHDRAWN | PHASE4 | 2017-06 | 2021-06 | 2021-06 |
| NCT03055234 | Study to Evaluate Efficacy and Safety of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Sickle Cell Disease (SCD) | WITHDRAWN | PHASE3 | 2017-06 | 2022-12 | 2021-12 |
| NCT03016468 | Safety of Transition From Selexipag to Remodulin® Then Oral Treprostinil in Symptomatic Adult PAH | WITHDRAWN | PHASE2 | 2017-05 | 2018-09 | 2018-09 |
| NCT03012646 | Safety and Tolerability of Inhaled Treprostinil in Adult PH Due to COPD | WITHDRAWN | PHASE2 | 2017-04 | 2019-04 | 2019-04 |
| NCT02630316 | Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE | COMPLETED | PHASE2, PHASE3 | 2017-02-03 | 2019-12-26 | 2019-12-26 |
| NCT02893995 | Safety, Tolerability, Pharmacokinetics and Efficacy of Two Different Rates of Subcutanous Remodulin® Dose Titration in Pulmonary Arterial Hypertension | WITHDRAWN | PHASE4 | 2017-02 | 2018-04 | 2018-04 |
| NCT02994238 | iTRACC (Improving Technology-Assisted Recording of Asthma Control in Children) | COMPLETED | NA | 2016-12 | 2018-12-31 | 2018-12 |
| NCT02633293 | An Open Label Extension Study to Evaluate Inhaled Treprostinil in Adult PH With ILD Including CPFE | TERMINATED | PHASE2, PHASE3 | 2016-09-15 | 2021-08-01 | 2021-08-01 |
| NCT02711163 | Evaluation of the Hypoallergenicity of an Extensively Hydrolyzed Formula | COMPLETED | PHASE3 | 2016-04 | 2017-11-29 | 2017-08-31 |
| NCT02710955 | SWAN: Study on the Tolerance and Efficacy of a New Anti-regurgitation Formula (PC-2016-01) | COMPLETED | NA | 2016-04-01 | 2017-04-12 | 2017-01-21 |
| NCT02603068 | Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis | WITHDRAWN | PHASE2 | 2016-02 | 2018-07 | 2018-04 |
| NCT02346760 | Study to Evaluate Safety, Tolerability, and Pharmacokinetics of UB-621 in Healthy Volunteers | COMPLETED | PHASE1 | 2015-12 | 2017-01 | 2017-01 |
| NCT02261883 | Remodulin as Add-on Therapy for the Treatment of Persistent Pulmonary Hypertension of the Newborn | TERMINATED | PHASE2 | 2015-07-29 | 2023-05-17 | 2022-09-27 |
| NCT02279745 | Long-term Safety and Efficacy of Ralinepag in Pulmonary Arterial Hypertension | COMPLETED | PHASE2 | 2015-07-08 | 2021-03-29 | 2021-03-29 |
| NCT02369146 | To Investigate the Safety and Efficacy of UB-421 Monotherapy in HIV Infected Adults | COMPLETED | PHASE2 | 2015-06 | 2016-07 | 2016-07 |
| NCT02276872 | Safety, Tolerability, and Pharmacokinetics of Oral Treprostinil in Pediatric PAH Patients Aged 7 to 17 Years | COMPLETED | PHASE2 | 2014-12-18 | 2017-07-20 | 2017-07-20 |
| NCT02279160 | Safety and Efficacy of APD811 in Pulmonary Arterial Hypertension | COMPLETED | PHASE2 | 2014-12 | 2017-06 | 2017-06 |
| NCT02318758 | Pharmacokinetic Interaction of Oral Treprostinil and Ethanol in Healthy Volunteers | COMPLETED | PHASE1 | 2014-09 | 2014-12 | 2014-10 |
| NCT02149095 | Dose Escalation, MTD, Safety and PK Study of a Single Dose SC Injection of TransCon PEG Treprostinil in Healthy Male Volunteers | WITHDRAWN | PHASE1 | 2014-07 | | 2014-11 |
| NCT02351531 | Cow Milk Allergy: Evaluation of the Efficacy of a New Thickened Extensively Hydrolyzed Formula in Infants With Confirmed Cow Milk Allergy | COMPLETED | PHASE3 | 2013-11 | | 2014-12 |
| NCT01560637 | An Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension | COMPLETED | PHASE3 | 2013-09-11 | 2021-08-12 | 2021-08-12 |
| NCT01934582 | A Pharmacokinetic Substudy of the TDE-PH-304 Protocol | COMPLETED | PHASE3 | 2013-08 | 2013-11 | 2013-11 |
| NCT02425423 | Study on the Tolerance and Efficacy of a New Anti Regurgitation Formula | COMPLETED | PHASE3 | 2013-06 | 2014-06 | 2014-03 |
| NCT01795950 | Safety Study of PLX-PAD Cells to Treat Pulmonary Arterial Hypertension (PAH) | TERMINATED | PHASE1 | 2013-04 | 2016-01 | 2015-12 |
| NCT01668043 | Study to Evaluate Safety and Efficacy of UB-421 Antibody in HIV-1 Infected Adults | COMPLETED | PHASE2 | 2012-09 | 2014-03 | 2014-03 |
| NCT01592045 | ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma | COMPLETED | PHASE1, PHASE2 | 2012-08 | 2014-06 | 2014-06 |
| NCT01746485 | Three Times Daily Dosing of UT-15C | COMPLETED | PHASE1 | 2012-07 | 2012-07 | 2012-07 |
| NCT01560624 | Phase III Clinical Worsening Study of UT-15C in Subjects With PAH Receiving Background Oral Monotherapy | COMPLETED | PHASE3 | 2012-06-26 | 2018-06-24 | 2018-06-24 |
| NCT01557660 | Inhaled Treprostinil for PAH: Open-label Extension | WITHDRAWN | PHASE3 | 2012-06 | 2018-12 | 2018-12 |
| NCT01557647 | Safety and Efficacy of Inhaled Treprostinil in Patients With PAH | WITHDRAWN | PHASE3 | 2012-06 | 2016-06 | 2015-12 |
| NCT02847260 | Safety and Tolerability of Rapid Dose Titration of Subcutaneous Remodulin® Therapy in PAH Subjects (RAPID) | COMPLETED | PHASE4 | 2012-04 | 2014-03 | 2014-03 |
| NCT01588405 | Remodulin® to Oral Treprostinil Transition | COMPLETED | PHASE2 | 2012-04 | 2014-12 | 2014-07 |
| NCT01768546 | Evaluation of Video On-Demand Programming to Prevent Type 2 Diabetes in Adults | COMPLETED | NA | 2012-02 | 2014-09 | 2013-05 |
| NCT01477333 | Addition of UT-15C SR to Pulmonary Arterial Hypertension Patients Currently Receiving Tyvaso® | COMPLETED | PHASE2 | 2011-10 | 2013-11 | 2013-11 |
| NCT01757925 | Evaluation of a Commercial Gaming Impact in a Childhood Obesity Intervention | COMPLETED | PHASE4 | 2011-08 | 2012-09 | 2012-09 |
| NCT01940068 | A Double-blind Randomized Controlled Trial of a Thickened Amino-acid-based Formula in Children Allergic to Cow's Milk and to Protein Hydrolysates | COMPLETED | NA | 2011-03 | 2013-12 | 2013-07 |
| NCT01985607 | Efficacy of a New Thickened Extensively Hydrolyzed Formula | COMPLETED | NA | 2011-02 | 2013-12 | 2013-07 |
| NCT01374646 | Community-based Program to Treat Childhood Obesity | COMPLETED | NA | 2011-01-01 | 2012-06-05 | 2012-06-05 |
| NCT01172496 | A Bioavailability Study Comparing Treprostinil Diethanolamine Oral Tablets and Oral Solution in Healthy Volunteers | COMPLETED | PHASE1 | 2010-08 | | 2010-08 |
| NCT01165476 | Comparative Bioavailability of Treprostinil Diethanolamine Manufactured by Two Independent Facilities | COMPLETED | PHASE1 | 2010-07 | 2010-08 | 2010-08 |
| NCT01153386 | Pharmacokinetic Linearity and Comparative Bioavailability of Treprostinil Diethanolamine | COMPLETED | PHASE1 | 2010-07 | 2010-08 | 2010-08 |
| NCT01131845 | The Effect of Renal Impairment on the Pharmacokinetics of Oral Treprostinil | COMPLETED | PHASE1 | 2010-05 | 2010-09 | 2010-09 |
| NCT01140126 | Study to Evaluate Safety and Pharmacokinetics of UB-421 Antibody in HIV-1 Infected Adults | COMPLETED | PHASE1 | 2010-05 | 2011-07 | 2011-07 |
| NCT01104870 | A Dose Response Study of UT-15C SR in Patients With Exercise-Induced Pulmonary Hypertension | COMPLETED | PHASE2 | 2010-04 | 2013-01 | 2013-01 |
| NCT00848107 | Open-Label Study of Oral Treprostinil in Digital Ulcers | TERMINATED | PHASE2 | 2009-09 | 2011-09 | 2011-09 |
| NCT00963027 | Effect of Esomeprazole on the Pharmacokinetics of Oral Treprostinil | COMPLETED | PHASE1 | 2009-09 | 2009-10 | 2009-10 |
| NCT00963001 | Effect of Food on the Pharmacokinetics of Oral Treprostinil | COMPLETED | PHASE1 | 2009-09 | 2009-11 | 2009-11 |
| NCT00969722 | A Study of MAb-3F8 Plus Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus 13-cis-Retinoic Acid (RA) Plus GM-CSF in Primary Refractory Neuroblastoma Patients | TERMINATED | PHASE2 | 2009-08 | | 2010-08 |
| NCT00887978 | Efficacy and Safety of Oral UT-15C Tablets to Treat Pulmonary Arterial Hypertension | COMPLETED | PHASE3 | 2009-06 | 2011-07 | 2011-07 |
| NCT00775463 | Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil Diethanolamine | COMPLETED | PHASE2 | 2009-05 | 2011-07 | 2011-03 |
| NCT00965588 | Study to Evaluate Safety, Tolerability and Immunogenicity of Vaccine (UB 311) in Subjects With Alzheimer's Disease | COMPLETED | PHASE1 | 2009-02 | 2011-04 | 2011-04 |
| NCT00760916 | FREEDOM DR: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor or as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH) | WITHDRAWN | PHASE3 | 2008-12 | 2009-01 | 2009-01 |
| NCT00848939 | Pharmacokinetics of Oral Treprostinil in Patients With Systemic Sclerosis | COMPLETED | PHASE1 | 2008-12 | 2010-04 | 2010-01 |
| NCT00741819 | Safety Evaluation of Inhaled Treprostinil Administration Following Transition From Inhaled Ventavis in Pulmonary Arterial Hypertension (PAH) Subjects | COMPLETED | PHASE4 | 2008-09 | 2010-12 | 2010-03 |
| NCT01884038 | Safety and Efficacy of Perioperative Remodulin® in Orthotopic Liver Transplant Recipients | WITHDRAWN | PHASE2, PHASE3 | 2008-06 | 2010-06 | 2010-06 |
| NCT00643604 | Rapid Switch From Flolan to Remodulin in the Outpatient Clinic | TERMINATED | PHASE4 | 2008-03 | 2012-02 | 2010-01 |
| NCT00458042 | Transitioning To IV Remodulin From Ventavis in Patients With PAH: Safety, Efficacy and Treatment Satisfaction | TERMINATED | PHASE4 | 2007-03 | 2007-11 | |
| NCT00439946 | Safety, Efficacy, and Treatment Satisfaction Switching From Flolan to Remodulin Using the Crono Five Ambulatory Pump in Patients With PAH | TERMINATED | PHASE4 | 2007-02 | 2011-03 | 2009-09 |
| NCT01027949 | An Open-Label Extension Trial of UT-15C Sustained-release (SR) in Subjects With Pulmonary Arterial Hypertension | COMPLETED | PHASE3 | 2007-01-16 | 2020-02-12 | 2020-02-12 |
| NCT00325442 | FREEDOM-C: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor for the Treatment of Pulmonary Arterial Hypertension (PAH) | COMPLETED | PHASE3 | 2006-10 | 2010-12 | 2008-09 |
| NCT00325403 | FREEDOM - M: Oral Treprostinil as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH) | COMPLETED | PHASE3 | 2006-10 | 2011-04 | 2011-04 |
| NCT00373360 | Safety, Efficacy and Treatment Satisfaction in Patients With PAH Rapidly Switched From Epoprostenol to Remodulin | COMPLETED | PHASE4 | 2006-09 | 2008-01 | 2008-01 |
| NCT03055221 | TRUST-2: Safety and Efficacy of Intravenous Remodulin® in Patients in India With Pulmonary Arterial Hypertension (PAH) | COMPLETED | PHASE4 | 2005-06-10 | 2014-02-25 | 2014-02-25 |
| NCT00147199 | Clinical Investigation Into Inhaled Treprostinil Sodium in Patients With Severe Pulmonary Arterial Hypertension (PAH) | COMPLETED | PHASE3 | 2005-06 | 2007-10 | 2007-10 |
| NCT00494533 | Study of Intravenous Remodulin in Patients in India With Pulmonary Arterial Hypertension | TERMINATED | PHASE4 | 2005-03 | 2005-10 | 2005-10 |
| NCT00069511 | 12 Week Study of Anti-Viral Effect of Oral UT-231B in Non-cirrhotic Hepatitis C Patients who have Failed Interferon-based Therapy. | UNKNOWN | PHASE2 | 2003-07 | 2004-12 | |
| NCT00067041 | Effects of Remodulin in Patients With Critical Limb Ischemia Following a Vein Bypass Graft | TERMINATED | PHASE2, PHASE3 | 2003-03 | 2003-12 | 2003-12 |
| NCT00060996 | Study of Remodulin in Patients With Critical Limb Ischemia With No Planned Revascularization Procedures | TERMINATED | PHASE3 | 2003-02 | 2004-09 | 2004-09 |
| NCT00058929 | A Transition Study From Flolan® to Remodulin® in Patients With Pulmonary Arterial Hypertension | COMPLETED | PHASE4 | 2002-10 | 2005-08 | 2005-08 |
| NCT01998074 | Evaluation of the Efficacy of a New Formula in Infants With Cow's Milk Protein Allergy | COMPLETED | NA | | | 2013-11 |
| NCT00002353 | A Phase I Safety and Immunogenicity Trial of UBI HIV Lipopeptide Immunotherapeutic P3C541b in HIV-1 Seropositive Human Subjects | COMPLETED | PHASE1 | | | |
| NCT00002428 | A Phase I/II Safety and Immunogenicity Trial of UBI Microparticulate Monovalent (HIV-1 MN) Branched Peptide Vaccine in HIV-1 Seronegative Human Subjects | COMPLETED | PHASE1 | | | |